Handokrella Fenjeong (Nabumetone)

Adult dose

Swallow this medicine without chewing (tablets only). Adults: Administer 1 g of nabumetone orally once daily at bedtime. If symptoms are severe or persistent, or worsen rapidly, administer an additional 500 mg∼1 g of this medicine orally in the morning. Elderly patients: As with many other medicines, blood concentrations may be higher in elderly patients. Do not exceed a maximum of 1 g per day; in some cases, satisfactory symptom relief may be achieved with a dose of 500 mg.

Child dose

Children: Clinical data on the use of this product in children are not yet available.

This medication should be used with caution by individuals who regularly consume more than three alcoholic beverages per day, as it may increase the risk of gastrointestinal bleeding; consultation with a doctor or pharmacist is essential. This medication may increase the risk of cardiovascular disease, so patients with a history of heart disease or stroke or those with risk factors should be particularly careful. During the course of this medication, cardiovascular symptoms should be carefully monitored; if symptoms arise, immediate consultation with medical personnel is advised. This medication can cause serious gastrointestinal adverse reactions such as gastrointestinal bleeding, ulcers, and perforations, so elderly patients or those with a history of gastrointestinal disease should be especially cautious. Patients with a history of gastrointestinal bleeding or ulcers should refrain from taking this medication, and dosages should be immediately stopped upon the appearance of gastrointestinal bleeding symptoms. This medication should not be administered to patients with peptic ulcers, severe liver disease, kidney disease, heart failure, drug hypersensitivity, or aspirin-sensitive asthma. Patients with chronic diseases, the elderly, or those with chronic kidney or liver disease should undergo regular monitoring of liver and kidney functions during treatment with this medication. This medication may cause severe allergic reactions, such as shock, anaphylaxis, severe skin reactions, or exacerbation of asthma; immediate discontinuation and treatment from medical personnel are required upon appearance of symptoms. Dizziness, drowsiness, or visual disturbances may occur during dosage; it is safer to avoid driving or handling dangerous machinery. Interactions may occur when taken concurrently with other non-steroidal anti-inflammatory drugs, anticoagulants, diuretics, lithium, methotrexate, etc., so consultation with medical personnel is necessary. Pregnant or potentially pregnant women and nursing mothers should not take this medication, especially during late pregnancy, as it may have serious effects on the fetus. Safety for children and adolescents under 15 years of age has not been established, so administration is not recommended. Elderly patients are at higher risk for gastrointestinal bleeding or perforation, so the minimum possible dose should be used, and symptoms of gastrointestinal bleeding should be closely monitored in the first four weeks of treatment. In the event of overdose, symptoms may include headache, nausea, vomiting, gastrointestinal bleeding, coma, etc.; if suspected, immediate medical attention should be sought for proper treatment. This medication should be kept out of reach of children and not transferred to other containers, as this is important for the safety and quality of the medication.

• Shock
• symptoms resembling anaphylaxis
• shortness of breath
• hives
• low blood pressure
• angioedema
• facial swelling
• rash
• itching
• dyspepsia

This medication should be stored in a sealed container to prevent air exposure, kept away from direct sunlight, and stored at room temperature. Room temperature typically refers to temperatures between 15 and 25 degrees Celsius, and extremes of heat or cold should be avoided.

Appearance

Caramel-scented, dark red oblong film-coated tablet.

Package unit

100 tablets, 30 tablets/bottle